High dose of tigecycline for extremely resistant Gram-negative pneumonia: Yes, we can

Critical Care

Volumn 18, Issue 3, 2014, Pages

  Garnacho Montero, José ^a   Ferrándiz Millón, Carmen ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPENEM; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; NOTE; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VENTILATOR ASSOCIATED PNEUMONIA; ANALOGS AND DERIVATIVES; CRITICAL ILLNESS; DRUG EFFECTS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; MALE; MULTIDRUG RESISTANCE; SEVERITY OF ILLNESS INDEX;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MINOCYCLINE; SEVERITY OF ILLNESS INDEX;

EID: 84902960778     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13942     Document Type: Note

References (15)

1. De Pascale G, Montini L, Pennisi MA, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014, 18:R90. 10.1186/cc13858, 4057423, 24887101.
2. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we?. Ann Clin Microbiol Antimicrob 2013, 12:22. 10.1186/1476-0711-12-22, 3846448, 23984642.
3. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R, . 308 Study Group Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009, 63:52-61. 10.1016/j.diagmicrobio.2008.09.001, 18990531, 308 Study Group.
4. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012, 16:R218. 10.1186/cc11862, 3672596, 23148736.
5. Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TW, Sánchez AS, Xin Z, Saulay M, Engelhardt M. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014, [Epub ahead of print].
6. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851. 10.1097/CCM.0b013e3181961bff, 19237886.
7. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009, 34:101-102. 10.1016/j.ijantimicag.2009.01.015, 19278835.
8. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011, 55:1162-1172. 10.1128/AAC.01402-10, 3067123, 21173186.
9. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012, 54:1699-1709. 10.1093/cid/cis270, 3404716, 22467668.
10. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013, 57:1756-1762. 10.1128/AAC.01232-12, 3623336, 23357775.
11. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, Casini B, Tascini C, Menichetti F. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013, 56:697-700. 10.1093/cid/cis969, 23155147.
12. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012, 55:943-950. 10.1093/cid/cis588, 22752516.
13. Balandin Moreno B, Fernández Simón I, Pintado García V, Sánchez Romero I, Isidoro Fernández B, Romera Ortega MA, Alcántara Carmona S, Pérez Redondo M, Galdos Anuncibay P. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis 2014, 46:175-180. 10.3109/00365548.2013.861608, 24354959.
14. Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB) (MagicBullet). [http://clinicaltrials.gov/ct2/show/NCT01292031].
15. Zimmermann JB, Horscht JJ, Weigand MA, Bruckner T, Martin EO, Hoppe-Tichy T, Swoboda S. Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline. Int J Antimicrob Agents 2013, 42:436-442. 10.1016/j.ijantimicag.2013.07.016, 24055255.